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9.1% had at least 14 urine losses per week. Level of symptoms
was closely related quality of life. Comparing the two groups,
we observed some relationships between level of symptoms and
socio-demographics. CONCLUSIONS: Prevalence of SUI in
French women was high. Women with SUI had a marked
decrease in their quality of life. There was an inverse relation
between level of urinary symptoms and quality of life: as the
intensity of symptoms increased, the quality of life decreased.
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OBJECTIVES: In October 2000, the ICD-9 diagnosis code
596.51 “Hypertonicity of Bladder” was updated to include
“Overactive Bladder” (OAB). Previously, no speciﬁc code iden-
tiﬁed OAB. To determine implications for outcomes estimates,
this study examined correspondence between suggested ICD-9
coding for OAB before the update and use of codes in claims
data. METHODS: Data were drawn from medical claims of
enrollees aged ≥18 years of a large US health plan. Fifteen ICD-
9 diagnosis codes that might indicate OAB were identiﬁed
through literature review and clinical consultation, and exam-
ined for agreement between sources. Possible OAB patients were
identiﬁed if an OAB ICD-9 code appeared in claims from August
31, 1999–March 1, 2000. RESULTS: Sources agreed completely
on ﬁve of 15 suggested ICD-9 codes. Of 33,290 patients with
suggested codes, 86% had 1 of the 5 codes, and only 1% had
596.51 “Hypertonicity of Bladder” before the added OAB
description. Most commonly used were “Urinary Frequency”
(788.41; 48% of possible patients), “Unspeciﬁed Urinary Incon-
tinence” (788.30; 19%), “Nocturia” (788.43; 15%), “Urge
Incontinence” (788.31; 8%), and “Mixed Incontinence, Urge
and Stress” (788.33; 5%). Proportion of subjects with the 5
codes differed by geographic region (p < 0.0001), but not by
gender (c2 = 3.30, p = 0.07). Of 15 codes, “Nocturia” (788.43)
was the only code with a greater proportion (74%) of men. Use
of the ﬁve primary codes showed a linear trend (p < 0.0001)
increasing from 81% in ages 18–35 to 91% in ages ≥75. CON-
CLUSIONS: Before the ICD-9 code update, ﬁve codes accounted
for most possible OAB patients and few were coded with 596.51.
We expect claims data following the October 2000 implementa-
tion will gradually shift to the updated OAB code. Research
should include 596.51 and the other ﬁve codes because coding
practices may change and demographic coding differences could
have an impact on outcomes estimates.
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OBJECTIVES: To analyse waiting lists and waiting times for
female patients with SUI in order to determine their burden on
Gynaecology and Urology National Health Service (NHS)
waiting lists waiting for SUI procedures. METHODS: The CHKS
hospital database in the UK was analysed over a two year period
for patients admitted for surgery between April, 2001 and
March, 2003. Speciﬁc SUI procedures were identiﬁed within
Gynaecology and Urology specialties and the number of cases
waiting for these procedures at speciﬁc time points was derived.
Results are presented as an average across the ﬁnancial year
2001–2002 as this data was considered most complete. Results
were stratiﬁed by England, Scotland and specialty. RESULTS:
England: 3.38% of patients on the Gynaecology waiting list and
2.90% of patients on the Urology waiting list are waiting for SUI
procedures. The mean and median wait times for Gynaecology
were 313 and 309 days respectively and for Urology 343 and
350 days respectively. The mean age of patients admitted to
Gynaecology was 54.76 and Urology was 56.98. Scotland:
4.25% of patients on the Gynaecology waiting list and 3.30%
of patients on the Urology waiting list are waiting for an SUI
procedure. The mean and median wait times for Gynaecology
were 175 and 142 days respectively and for Urology 268 and
275 days respectively. The mean age of patients admitted to
Gynaecology was 51.64 and Urology was 54. CONCLUSIONS:
The percentage of patients waiting for an SUI procedure repre-
sents a signiﬁcant burden on the NHS where, in England, there
is an average of 2866 patients on the gynaecology waiting list
and 2080 on the Urology waiting list in any one quarter between
2001–2002 waiting for SUI procedures. Any new treatment
reducing the need for SUI procedures could potentially have a
noticeable impact on waiting lists in the NHS.
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OBJECTIVES: To collect and compare unit costs for resource
use data in PURE, an observational study with the primary
objective to determine the direct cost of urinary incontinence (UI)
treatment in Europe. METHODS: Resource use data include
medication, conservative treatment, diagnostic and surgical pro-
cedures, incontinence products and visits to health care
providers. Unit costs by country and type were collected using a
standardized data collection form. OECD consumer price indices
and purchasing power parity ﬁgures were used to convert prices
into 2003/2004 values and US dollars respectively. Prices were
then converted into Euros using an exchange rate of 1$ = 0.84€
(June 2004). RESULTS: Unit costs were derived from standard
national pricelists for medications, retail prices for incontinence
products, DRG (Diagnosis-related Groups) data for surgical
interventions where applicable, or costs of procedures and
overnight stays derived from hospitals in the remaining coun-
tries. The costs of conservative therapy, incontinence products
and health care visits varied between countries within reasonable
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limits due to different health care systems and practice patterns.
Health care contacts were reported at a range of 10€ or less to
260€ depending on the type of provider. For diagnostic inter-
ventions similar costs were observed across the countries, except
for more complex procedures. The cost of an urodynamic test
was within the range of 70–175€ other than in Denmark (13€)
and Spain (260€). For countries with DRG systems variability in
unit costs of surgical procedures for UI appears low. In non-DRG
systems procedure costs (including length of stay in surgical
wards) are comparable to DRGs. CONCLUSIONS: Unit costs
for UI treatment vary between the differing healthcare settings
within Europe. The standardized collection of unit cost data in
PURE is the prerequisite for determining UI-related costs of care
in this multinational setting.
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OBJECTIVE: Hyperphosphataemia in patients with end-stage
renal disease can affect mineral homeostasis, resulting in sec-
ondary hyperparathyroidism, osteodystrophy and vascular cal-
ciﬁcation. Several phosphate binders are currently available;
however, they are associated with a range of side effects. Lan-
thanum carbonate is a new phosphate binder that effectively con-
trols serum phosphorus levels. METHODS: We assessed the cost
effectiveness of lanthanum carbonate as a second-line treatment
for patients inadequately controlled using maximum doses of
calcium-based phosphate binders as recommended by the
National Kidney Foundation (USA). Quality-adjusted life years
(QALYs) gained were used as the measure of effectiveness, and
the standard for cost per QALY gained adopted as the threshold
for cost effectiveness was that of the National Institute for Clin-
ical Excellence (NICE) in the UK. The clinical pathways model
used to estimate cost effectiveness had the following structure:
1) Patients who failed on calcium carbonate received a trial
period on lanthanum carbonate; 2) Those who succeeded on lan-
thanum carbonate continued to receive it; 3) Those who failed
on lanthanum carbonate switched back to calcium carbonate; 4)
Serum phosphorus levels were estimated for each subgroup using
clinical trial results; 5) Implied relative risk of mortality (based
on Block et al) was applied to USRDS survival data and thus
QALYs gained were calculated; and 6) Treatment costs were
attached to each pathway. RESULTS: The results demonstrate
that lanthanum carbonate is cost effective at conventional NICE
thresholds for patients whose phosphorus level remains above
6.6mg/dL (2.1mmol/L) when treated with calcium carbonate.
CONCLUSION: For patients who achieve a phosphorus level
below 6.6mg/dL on calcium carbonate, lanthanum carbonate is
unlikely to be cost effective on reasonable assumptions about its
price. Lanthanum carbonate becomes progressively more cost
effective with increasing phosphorus levels for patients treated
with calcium carbonate.
